First-in-class topical
hydrogel applied directly
onto a chronic wound
Real
Breakthrough
Designed to move the wound from chronicity to regeneration
Reduces pain, inflammation, and amputation risk
Direct Topical delivery via therapeutic gel
Fight infection, and regenerate skin
Safe, targeted, and easy to administer
Deliver a cost-effective solution at scale
All-in-one solution
addressing simultaneously
all chronicity inducing factors
Properties
Wide spectrum biofilm inhibition & disruption
Wide spectrum bacteriostatic and bactericide
Protease activity regulation
↑ In situ oxygenation
Acidification of the wound
bed toward healing pH
Free-radicals scavenging
Displacement from the chronic inflammatory state
↑ Granulation tissue formation
↑ Reepithelialization
↓ Neuropathic and nociceptive pain
Exudate management
Activation of autolytic debriding
International
Footprint
Science-driven
Patient-centered
Our therapy is the result of years of research and development — driven by a single principle: to create the best possible treatment for patients.
Every stage has been carefully refined, integrating scientific rigor with a deep understanding of the real-world challenges patients face. Not to develop another product, but to build a solution that truly works.
This commitment has guided each iteration — raising the standard, improving performance, and bringing us closer to a therapy capable of addressing the full complexity of chronic wounds.
Today, this work translates into a high-quality therapy being developed under the most rigorous GMP standards, ensuring consistency, safety, and scalability.
Because excellence in science only matters when it delivers real outcomes for patients.
Strategic partnership
with Elea for Latin America
Untech has partnered with Elea, one of the leading pharmaceutical companies in Latin America, to bring this breakthrough therapy to patients across the region.
This partnership combines Untech’s innovation with Elea’s proven expertise in development, regulatory pathways, and large-scale commercialization—ensuring the highest quality standards from production to patient access.
With a strong track record of delivering high-quality pharmaceutical products and an extensive distribution network, Elea has the capability to bring this therapy to every corner of Latin America.
“Millions of patients don’t
need better dressings — they
need a new therapeutic paradigm”
Every 20 seconds…
Someone loses a limb
due to a chronic wound.
A global Unmet
Medical Need
An estimated 167 million people with diabetes will develop diabetic foot ulcers (DFUs), and about one-third of these will become hard-to-heal chronic wounds.
Despite best efforts, standard treatments fall short for hard-to-heal diabetic wounds—contributing to
amputation in 1 out of every 5 cases.
Million of Patients with Venous leg ulcers (VLU) and Bedsores suffer the same. Chronic pain and amputations.
A multi-billion
opportunity
A Large inefficient market,
ready for disruption.
A Company
ready to Scale
Patients lack definitive solutions.
Systems absorb rising costs.
Healthcare systems in Europe and the US alone spend over €80-90 billion annually treating chronic wounds. Yet current treatments remain costly and do not ensure healing.
Untech is changing that.
With a breakthrough therapy designed to drive healing, we are approaching market entry and preparing to scale globally
- A large unmet need.
- A broken system.
- A unique solution built to scale.
One product
Multiple mechanisms
Real healing
About us &
Our vision
Untech is a drug development company rethinking chronic wound care.
We were created with a clear purpose: to move beyond palliative solutions and deliver real healing to patients.
Chronic wounds are not driven by a single factor, but by a complex and self-sustaining microenvironment.
Most therapies address these factors in isolation — and that is why healing often fails.
Our novel approach is designed to act differently.
By targeting the full complexity of the wound simultaneously, we aim to shift wounds out of chronicity and enable true healing.
This is not about improving existing treatments.
It’s about redefining what effective treatment should be.
Patient needs define everything we build.
Our goal is to make true healing accessible at scale — across healthcare systems and geographies.
Global Awards
& Recognition
Korea-LAC Summit, organizated by Inter-American Development Bank and the Ministry of Economy and Finance of Korea
IMPACTEC Contest, organizated by Buenos Aires City Hall and Singularity University
100K Latam Contest Organized by MIT and ITBA
Samsung Innova Contest Organized by Samsung
IB50K Contest, Organized by the Balseiro Institute
SINAPTEC Innovation Program, organizated by Stanford University, LATIPNET Foundation and Government of the City of Bs. As
Everis Scientific Entrepreneurship Award – Biotech and Health
IAE Business School – Business Idea Award Austral University
Second Ibero Latin American Congress of ulcers and wounds www.silauhe.org
Second & third International Congress of Pharmaceutical Sciences www.ricifa.com.ar
Fourth International Simposium of Lactic Acid Bacteria
XLIII Congreso de la Sociedad Argentina Farmacología Experimental
Partner with us
We are expanding our international presence beyond Latin America and actively seeking partners across the United States, Europe, and Asia to bring this therapy to patients worldwide.
If you are a clinician, investor, or industry partner interested in advancing the future of wound care, we would welcome the opportunity to connect.
Email: [email protected]
Address: Suipacha 1111, CABA, Argentina
LinkedIn: untech-bio
